Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Business Wire July 21, 2016

Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines

Business Wire July 14, 2016

Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors

Business Wire July 5, 2016

9 Biggest Mid-Day Losers For Tuesday

Benzinga.com  June 14, 2016

Mid-Day Market Update: Yingli Green Energy Surges Following Q1 Earnings; Infinity Pharmaceuticals Shares Tumble

Benzinga.com  June 14, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  June 14, 2016

Microsoft-LinkedIn Deal Highlights Underlying M&A Trend In Internet Landscape

Benzinga.com  June 14, 2016

Mid-Morning Market Update: Markets Mostly Lower; Isle of Capri Casinos Profit Beats Views

Benzinga.com  June 14, 2016

12 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  June 14, 2016

7 Stocks You Should Be Watching Today

Benzinga.com  June 14, 2016

Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines

GlobeNewswire June 13, 2016

Xiao Nan Guo Agrees to Acquire a 9.82% Stake in Wowo Limited

GlobeNewswire June 13, 2016

Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio

GlobeNewswire June 2, 2016

Revance to Participate in Upcoming Investor Conferences

GlobeNewswire May 31, 2016

Revance Releases First Quarter 2016 Results

GlobeNewswire May 9, 2016

Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016

GlobeNewswire April 25, 2016

Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development

GlobeNewswire March 14, 2016

Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology

GlobeNewswire March 5, 2016

Revance Releases Fourth Quarter and Full Year 2015 Results

GlobeNewswire March 2, 2016

Revance to Participate in Upcoming Investor Conferences

GlobeNewswire February 23, 2016